Department of Pediatrics

Education

• DDS, Asahi University School of Dentistry, 1991
• PhD, Mie University, School of Medicine, 2003
• DDS, Mie Univ School of Medicine, 1993
• DDS, Mie University School of Medicine, 2002

Honors

• American Society for Bone and Mineral Research Young Investigator Award, 2004
• American Society for Bone and Mineral Research Travel Award, 2007
• North American Grant Award (Exiqon), 2009

Recent Publications view all (23)

Publication Co-Authors

Keith A. Hruska, M.D.

Washington University has a long tradition of collaboration amongst colleagues.The faculty above have co-authored publications with Toshifumi Sugatani, DDS, Ph.D.

1. Hruska KA, Sugatani T, Agapova O, Fang Y. The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology. Bone. 2017;100:80-86. PMCID:PMC5502716  PMID:28119179 
2. Sugatani T, Agapova OA, Fang Y, Berman AG, Wallace JM, Malluche HH, Faugere MC, Smith W, Sung V, Hruska KA. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease. Kidney Int. 2017;91(1):86-95. PMCID:PMC5530394  PMID:27666759 
3. Agapova OA, Fang Y, Sugatani T, Seifert ME, Hruska KA.. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int. 2016;89(6):1231-43. doi:10.1016/j.kint.2016.02.002.  PMID:27165838 
4. Sugatani T, Agapova O, Malluche HH, Hruska KA. SIRT6 deficiency culminates in low-turnover osteopenia. Bone. 2015;81:168-177. doi:10.1016/j.bone.2015.07.018  PMID:26189760 
5. Hruska KA, Seifert M, Sugatani T. Pathophysiology of the chronic kidney disease-mineral bone disorder. Curr Opin Nephrol Hypertens. 2015;24(4):303-9. doi:10.1097/MNH.0000000000000132  PMID:26050115 
6. Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, Freedman BI, Monier-Faugere MC, Malluche H, Hruska KA. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol. 2014;25(8):1760-73. doi:10.1681/ASN.2013080818  PMCID:PMC4116062  PMID:24578135 
7. Sugatani T, Hildreth BE 3rd, Toribio RE, Malluche HH, Hruska KA. Expression of DGCR8-dependent microRNAs is indispensable for osteoclastic development and bone-resorbing activity. J Cell Biochem. 2014;115(6):1043-7. doi:10.1002/jcb.24759  PMCID:PMC4079251  PMID:24420069 
8. Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int. 2014;85(1):142-50. doi:10.1038/ki.2013.271  PMCID:PMC3836911  PMID:23884339 
9. Sugatani T, Hruska KA. Down-regulation of miR-21 biogenesis by estrogen action contributes to osteoclastic apoptosis. J Cell Biochem. 2013;114(6):1217-22. doi:10.1002/jcb.24471  PMID:23238785 
10. Hruska K, Mathew S, Lund R, Fang Y, Sugatani T. Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? Kidney Int Suppl. 2011;(121):S9-13. PMCID:PMC3260961  PMID:21346719 
11. Sugatani T, Vacher J, Hruska KA. A microRNA expression signature of osteoclastogenesis. Blood. 2011;117(13):3648-57. doi:10.1182/blood-2010-10-311415  PMCID:PMC3072882  PMID:21273303 
12. Sugatani T, Hruska KA. Impaired micro-RNA pathways diminish osteoclast differentiation and function. J Biol Chem. 2009;284(7):4667-78. doi:10.1074/jbc.M805777200  PMCID:PMC2640963  PMID:19059913 
13. Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol. 2008;19(6):1092-105. doi:10.1681/ASN.2007070760  PMCID:PMC2396927  PMID:18417722 
14. Sugatani T, Hruska KA. MicroRNA-223 is a key factor in osteoclast differentiation. J Cell Biochem. 2007;101(4):996-9. doi:10.1002/jcb.21335  PMID:17471500 
15. Sugatani T, Hruska KA. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem. 2005;280(5):3583-9. doi:10.1074/jbc.M410480200  PMID:15545269 
16. Sugatani T, Alvarez UM, Hruska KA. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem. 2003;90(1):59-67. doi:10.1002/jcb.10613  PMID:12938156 
17. Sugatani T, Alvarez U, Hruska KA. PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility. J Biol Chem. 2003;278(7):5001-8. doi:10.1074/jbc.M209299200  PMID:12460992 
18. Murata T, Sugatani T, Shimizu K, Manganiello VC, Tagawa T. Effect of the phosphodiesterase 4 inhibitor, rolipram, on retinoic acid-increased alkaline phosphatase activity in the mouse fibroblastic C3H10T1/2 cell line. Arch Oral Biol. 2003;48(1):63-7. PMID:12615143 
19. Murata T, Sugatani T, Manganiello VC, Shimizu K, Tagawa T. Expression of phosphodiesterase 3 in rat submandibular gland cell lines. Arch Oral Biol. 2001;46(5):453-7. PMID:11286810 
20. Murata T, Sugatani T, Shimizu K, Manganiello VC, Tagawa T. Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular gland. Anticancer Drugs. 2001;12(1):79-83. PMID:11272291 
21. Murata T, Sugatani T, Tagawa T. Expression of phosphodiesterase 3 in rat submandibular gland. Arch Oral Biol. 2000;45(12):1043-7. PMID:11084143 
22. Nomura J, Tagawa T, Seki Y, Mori A, Nakagawa T, Sugatani T. Kinky hair disease with multiple eruption cysts: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;82(5):537-40. PMID:8936518 
23. Sugatani T, Inui M, Tagawa T, Seki Y, Mori A, Yoneda J. Myofibroma of the mandible. Clinicopathologic study and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;80(3):303-9. PMID:7489274